<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04739215</url>
  </required_header>
  <id_info>
    <org_study_id>FIBHGM-CARDIA-STIFF</org_study_id>
    <secondary_id>2019-002046-20</secondary_id>
    <nct_id>NCT04739215</nct_id>
  </id_info>
  <brief_title>Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF</brief_title>
  <acronym>CARDIA-STIFF</acronym>
  <official_title>Effects of Sodium-Glucose Cotransporter 2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación para la Investigación Biomédica del Hospital Gregorio Maranon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to identify the underlying mechanisms of Sodium-glucose&#xD;
      co-transporter-2 (SGLT2) inhibitors which are associated to better outcomes in patients with&#xD;
      Diabetes mellitus type 2 and Heart Failure with preserved Ejection Fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double design study including a clinical trial and a nested case-control study.&#xD;
&#xD;
      A) Experimental study (clinical trial): Phase IV, prospective, randomized, double-blind&#xD;
      placebo-controlled with 12 months follow-up. Inclusion criteria are: 1) diagnosis of DM2, 2)&#xD;
      HF with preserved EF with a hospital admission in the previous 6 months with demonstration of&#xD;
      diastolic dysfunction. 3) Stable clinical situation at inclusion. 4) Clinical indication of&#xD;
      cardiac catheterization.&#xD;
&#xD;
      Patients will be randomized 1:1 to received Dapagliflozin 10 mg/day or placebo. The main&#xD;
      objective is to compare the impact of the drug on LV diastolic properties at the peak of&#xD;
      effort and in levels of plasma deposit and cross-linking biomarkers of type I collagen&#xD;
      between the two treatment groups at baseline and after 12 months.&#xD;
&#xD;
      52 patients will be recruited.&#xD;
&#xD;
      B) Descriptive study: Nested case-control study, considering patients from the experimental&#xD;
      study as cases and 10 additional patients with HF with preserved EF but no type 2 DM as&#xD;
      controls. The main aim will be compare the histological, molecular, biochemical and&#xD;
      biomechanical features of the HFpEF patients with and without DM2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Main Objective: Impact of iSGLT2 on LV diastolic properties in terms of the change in LV stiffness constant (S+) at the peak of exercise.</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>Intrinsic diastolic properties will be analyzed by dynamic pressure-volume loop catheterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main Structural Objective: Changes in serum levels of procollagen type I C-terminal propertied (PICP, ng/mL)</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>We will measure the changes in serum levels of procollagen type I C-terminal propertied (PICP, ng/mL), a validated biomarker of collagen type I deposition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in LV stiffness constants (S+ and S-).</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>LV stiffness constants will be obtained from invasive pressure-volume data analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the slope, Emax, of the end-systolic pressure-volume relationship</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>Emax will be obtained from invasive pressure-volume data analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of iSGLT2 on myocardial remodeling.</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>Reverse cardiac remodeling will be studied by cardiac magnetic resonance (CMR). CMR studies will be performed on 1.5 T scanners and will include short-axis cine steady-state free-precession images from base to apex, and standard long axis views for the analysis of mass, volume and ventricular function.&#xD;
CMR study will require the administration of a gadolinium contrast medium to study myocardial fibrosis, unless contraindicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of myocardial remodeling patterns with the intrinsic diastolic properties of chamber VI with systolic function.</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>Results from the pressure-volume analysis and CMR will be assess in common in order to search for association.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative contribution of the intrinsic diastolic properties of the LV and the flow patterns on filling pressures and their modulation under treatment with iSGLT2.</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>Intraventricular flow patterns will be studied by Doppler echocardiography and phase contrast CMR, considering vorticity and blood transport parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum levels of collagen type I C-terminal telopeptide to matrix metalloproteinase ratio (CITP:MMP-1)</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>We will measure the changes in serum levels of collagen type I C-terminal telopeptide to matrix metalloproteinase ratio (CITP:MMP-1), biomarker of the degree of collagen type cross-linking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in N-terminal pro brain natriuretic peptide (pg/mL)</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>We will measure the changes in N-terminal pro brain natriuretic peptide (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in high sensitivity troponin T (pg/mL)</measure>
    <time_frame>Baseline vs 12 months</time_frame>
    <description>We will measure the changes in high sensitivity troponin T (pg/mL)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Clinical Trial: Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Dapagliflozin (Forxiga) 10 mg, one capsule per day orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical Trial: Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus treated with Placebo in a similar pattern.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Descriptive Study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with heart failure with preserved ejection fraction but with no type 2 diabetes mellitus (n=10).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG [Farxiga]</intervention_name>
    <description>Dapagliflozin 10 mg / day oral</description>
    <arm_group_label>Clinical Trial: Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One Placebo capsule daily oral</description>
    <arm_group_label>Clinical Trial: Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of DM2 based on the established criteria: HbA1c ≥ 6.5% (48 mmol / mol) and&#xD;
             fasting plasma glucose ≥ 7.0 mmol / L (≥126 mg / dL) or 2-h after overload ≥ 11.1 mmol&#xD;
             / L ( ≥ 200 mg / dL).&#xD;
&#xD;
          -  LVEF ≥ 50%.&#xD;
&#xD;
          -  Diagnosis of ICFEP according to clinical criteria, with a hospital admission in the&#xD;
             previous 6 months with demonstration of diastolic dysfunction according to the&#xD;
             echocardiographic criteria.&#xD;
&#xD;
          -  Stable clinical situation (&gt; 1 month after hospitalization due to IC decompensation).&#xD;
&#xD;
          -  Clinical indication of cardiac catheterization.&#xD;
&#xD;
          -  Signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with iSGLT2.&#xD;
&#xD;
          -  Significant coronary disease.&#xD;
&#xD;
          -  Aortic or mitral valve disease ≥ moderate (grades 3 or 4/4 for valve regurgitations)&#xD;
&#xD;
          -  Contraindications for dapagliflozin treatment according to the data sheet (hereditary&#xD;
             galactose intolerance, Lapp lactase insufficiency or glucose-galactose malabsorption,&#xD;
             moderate-severe renal failure -CrCl &lt;60 ml / min or eGFR &lt;60 ml / min / 1 , 73 m2-,&#xD;
             severe hepatic insufficiency).&#xD;
&#xD;
        The inclusion/exclusion criteria for Descriptive Study will be the same as previously&#xD;
        described without the diagnosis of DM2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Bermejo Thomas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Bermejo Thomas, MD, PhD</last_name>
    <phone>(34) 91 5868279</phone>
    <email>javier.bermejo@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>280007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Bermejo Thomas, MD, PhD</last_name>
      <phone>(34) 91 5868815</phone>
      <email>javier.bermejo@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Bermejo Thomas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adolfo Villa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia Delgado Montero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Rodríguez Gonzalez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaime Elízaga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria del Mar Desco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Carlos del Álamo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Carlos Antoranz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Kasner M, Westermann D, Lopez B, Gaub R, Escher F, Kühl U, Schultheiss HP, Tschöpe C. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011 Feb 22;57(8):977-85. doi: 10.1016/j.jacc.2010.10.024.</citation>
    <PMID>21329845</PMID>
  </results_reference>
  <results_reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </results_reference>
  <results_reference>
    <citation>Pérez Del Villar C, Savvatis K, López B, Kasner M, Martinez-Legazpi P, Yotti R, González A, Díez J, Fernández-Avilés F, Tschöpe C, Bermejo J. Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. Cardiovasc Res. 2017 Jul 1;113(8):906-914. doi: 10.1093/cvr/cvx047.</citation>
    <PMID>28402411</PMID>
  </results_reference>
  <results_reference>
    <citation>Bermejo J, Yotti R, Pérez del Villar C, del Álamo JC, Rodríguez-Pérez D, Martínez-Legazpi P, Benito Y, Antoranz JC, Desco MM, González-Mansilla A, Barrio A, Elízaga J, Fernández-Avilés F. Diastolic chamber properties of the left ventricle assessed by global fitting of pressure-volume data: improving the gold standard of diastolic function. J Appl Physiol (1985). 2013 Aug 15;115(4):556-68. doi: 10.1152/japplphysiol.00363.2013. Epub 2013 Jun 6.</citation>
    <PMID>23743396</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

